Invest
EU policy reforms and pharma investments highlight shifting industry priorities
Invest
EU policy reforms and pharma investments highlight shifting industry priorities
In a significant move to bolster the pharmaceutical landscape across Europe, the European Parliament's rapporteur has unveiled draft reforms to the proposed EU Critical Medicines Act. These reforms aim to enhance investment in domestic manufacturing and expand stockpiling measures, ensuring a steady supply of medicines across EU member states. The draft legislation broadens the definition of "medicines of common interest" and extends investment incentives beyond just critical medicines. It also introduces multi-winner procurement, minimum supply commitments, and an EU coordination mechanism to manage shortages. This initiative signals a shift in industry priorities, according to GlobalData, a leading data and analytics company.
EU policy reforms and pharma investments highlight shifting industry priorities
In a significant move to bolster the pharmaceutical landscape across Europe, the European Parliament's rapporteur has unveiled draft reforms to the proposed EU Critical Medicines Act. These reforms aim to enhance investment in domestic manufacturing and expand stockpiling measures, ensuring a steady supply of medicines across EU member states. The draft legislation broadens the definition of "medicines of common interest" and extends investment incentives beyond just critical medicines. It also introduces multi-winner procurement, minimum supply commitments, and an EU coordination mechanism to manage shortages. This initiative signals a shift in industry priorities, according to GlobalData, a leading data and analytics company.
Eóin Ryan, Manager of Health Economics and Market Access at GlobalData, commented on the implications of these proposals: “The proposals strengthen investment channels for both common and critical medicines and reinforce Europe’s manufacturing base. However, expanding stockpiling obligations could increase administrative and cost burdens for companies already facing tight margins.”
The discussions surrounding these reforms are set to continue into 2026, as the EU seeks to strike a balance between strategic autonomy and market efficiency. The emphasis on domestic manufacturing and stockpiling is seen as a response to recent global supply chain disruptions and the need for Europe to ensure its pharmaceutical independence.
In parallel with these policy developments, significant investments in the pharmaceutical sector are unfolding on the other side of the Atlantic. GlobalData’s Bio/Pharmaceutical Outsourcing Report highlights GSK's announcement of a massive $30 billion, five-year investment to expand its R&D and manufacturing capabilities in the United States. This investment includes $1.2 billion earmarked for advanced technologies and the construction of a new biologics flex factory in Upper Merion, Pennsylvania, slated to begin in 2026.
GSK CEO Emma Walmsley has emphasised the company's continued commitment to its UK roots, stating that GSK will keep investing over $2.3 billion annually in research and development. This dual investment strategy underscores GSK’s approach to balancing its global presence. Janet Beal, Managing Analyst for Health Economics and Market Access at GlobalData, noted: “GSK’s dual investment strategy demonstrates a clear commitment to strengthening its US footprint while maintaining confidence in its UK base. This approach reflects a broader industry trend to balance global competitiveness amid shifting policy and trade dynamics.”
The landscape of pharmaceutical investment is further enriched by FUJIFILM Biotechnologies USA's announcement of a $2 billion investment, funded by Johnson & Johnson. This investment will be used to construct a 160,000-square-foot facility at its Holly Springs site, creating approximately 120 new jobs and expanding US capacity for advanced medicines. Meanwhile, Capitol Biologics is set to offer comprehensive early-phase biologics development and GMP manufacturing services for private biotech firms and US government agencies. These services will adhere to a unified quality system aligned with FDA, EMA, and ICH standards.
The Bio/Pharmaceutical Outsourcing Report, a monthly analysis of trends affecting pharmaceutical contract manufacturing organisations (CMOs), provides insights into the latest contract manufacturing agreements, opportunities, and threats for CMOs, as well as mergers and acquisitions and emerging regulatory news.
These developments highlight a broader trend within the pharmaceutical industry, where companies are navigating a complex web of policy changes and investment opportunities to secure their positions in an increasingly competitive global market. As the EU works towards greater strategic autonomy, and companies like GSK and FUJIFILM Biotechnologies USA expand their investment portfolios, the industry is poised for transformative changes that could redefine the future of pharmaceutical manufacturing and supply.
RELATED ARTICLES
Investment insights
Payday Super could prompt a wave of business sales in Australia
As Australian small business owners brace for the introduction of Payday Super on 1 July 2026, industry experts are sounding alarms about the potential impact on the nation's business landscapeRead more
Investment insights
Value stocks back in favour as federal budget bolsters income investing
The recent federal budget, coupled with shifting macroeconomic conditions, is casting a spotlight on the appeal of value stocks and income-generating businesses. This trend is being observed as a ...Read more
Investment insights
A fortnight of flux: Australian investors brace for economic shifts and corporate updates
The past fortnight has been marked by a whirlwind of developments in the financial markets, with investor attention riveted on both domestic and international fronts. From the looming tax policy ...Read more
Investment insights
Shifting global conditions and policy changes shape Australian investment landscape
In a series of events held across Australia last week, Shadforth Financial Group's annual State of the Nation gatherings brought together industry experts to discuss the evolving investment ...Read more
Investment insights
European start-ups demand faster funding and reduced red tape amid new Chips Act proposal
As the European Commission prepares to unveil its Chips Act II proposal on May 27, the spotlight turns to the challenges faced by European start-ups in the semiconductor and deep tech sectorsRead more
Investment insights
New business registrations rise in April, but GST drop points to more cautious founders
In a testament to the enduring entrepreneurial spirit in Australia, new business registrations surged in April 2026, marking a 6.41% increase compared to the same period last year. According to the ...Read more
Investment insights
Investors face mixed outcomes in latest budget, say industry leaders
In the wake of the recent budget announcements, industry leaders from Spaceship Financial Services and eToro Australia have expressed their views on the implications for investors, highlighting a mix ...Read more
Investment insights
Changes to CGT rules spark concern among Australian startup founders
The recent announcement of changes to the Capital Gains Tax (CGT) in the 2026-27 budget has sent ripples of concern through Australia's startup community. Founders and investors alike are expressing ...Read more
Investment insights
Payday Super could prompt a wave of business sales in Australia
As Australian small business owners brace for the introduction of Payday Super on 1 July 2026, industry experts are sounding alarms about the potential impact on the nation's business landscapeRead more
Investment insights
Value stocks back in favour as federal budget bolsters income investing
The recent federal budget, coupled with shifting macroeconomic conditions, is casting a spotlight on the appeal of value stocks and income-generating businesses. This trend is being observed as a ...Read more
Investment insights
A fortnight of flux: Australian investors brace for economic shifts and corporate updates
The past fortnight has been marked by a whirlwind of developments in the financial markets, with investor attention riveted on both domestic and international fronts. From the looming tax policy ...Read more
Investment insights
Shifting global conditions and policy changes shape Australian investment landscape
In a series of events held across Australia last week, Shadforth Financial Group's annual State of the Nation gatherings brought together industry experts to discuss the evolving investment ...Read more
Investment insights
European start-ups demand faster funding and reduced red tape amid new Chips Act proposal
As the European Commission prepares to unveil its Chips Act II proposal on May 27, the spotlight turns to the challenges faced by European start-ups in the semiconductor and deep tech sectorsRead more
Investment insights
New business registrations rise in April, but GST drop points to more cautious founders
In a testament to the enduring entrepreneurial spirit in Australia, new business registrations surged in April 2026, marking a 6.41% increase compared to the same period last year. According to the ...Read more
Investment insights
Investors face mixed outcomes in latest budget, say industry leaders
In the wake of the recent budget announcements, industry leaders from Spaceship Financial Services and eToro Australia have expressed their views on the implications for investors, highlighting a mix ...Read more
Investment insights
Changes to CGT rules spark concern among Australian startup founders
The recent announcement of changes to the Capital Gains Tax (CGT) in the 2026-27 budget has sent ripples of concern through Australia's startup community. Founders and investors alike are expressing ...Read more
